ALMANAC
ALMANAC
ALMANAC (pronounced: /ˈɑːlməˌnæk/), is an acronym in the medical field that stands for "Atrial Fibrillation Management: An Evidence-Based Approach to Lowering Mortality and Avoiding Clinical Complications". It is a clinical trial that aims to improve the management of atrial fibrillation and reduce the risk of stroke and other complications.
Etymology
The term "ALMANAC" is an acronym derived from the initial letters of the clinical trial it represents. The word "almanac" itself originates from the Arabic "al-manakh", which means "the weather".
Related Terms
- Atrial Fibrillation: A heart condition that causes an irregular and often abnormally fast heart rate. It is the condition that the ALMANAC trial aims to manage more effectively.
- Clinical Trial: A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
- Stroke: A medical condition in which poor blood flow to the brain results in cell death. It is one of the complications that the ALMANAC trial aims to prevent.
- Complication: An unfavorable evolution or consequence of a disease, a health condition, or a therapy. The term refers to unfavorable conditions that occur during the course of a disease, usually as a result of the disease itself or as a result of the treatment.
External links
- Medical encyclopedia article on ALMANAC
- Wikipedia's article - ALMANAC
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski